{
    "2021-11-18": [
        [
            {
                "time": "2022-01-01",
                "original_text": "Pfizer CEO Talks About Covid Vaccines and What Comes Next: ‘I Think We Are Undervalued.’",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "CEO",
                        "Covid",
                        "Vaccines",
                        "Undervalued"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-01-01",
                "original_text": "Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Aducanumab",
                        "CHMP",
                        "Negative",
                        "Trend",
                        "Vote"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-01-01",
                "original_text": "Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Vir",
                        "Sotrovimab",
                        "COVID",
                        "Government"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-01-01",
                "original_text": "Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients",
                "features": {
                    "keywords": [
                        "Emgality",
                        "Nurtec",
                        "Migraine",
                        "Preventive",
                        "Treatment",
                        "Study",
                        "Patients"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2022-01-01",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Eli Lilly",
                        "Pfizer",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}